Print this page
-
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma.
Protocol: 142202Principal Investigator:
- Vincent Yeung (Rutgers Cancer Institute of New Jersey-University Hospital)
Applicable Disease Sites: Brain and Nervous System -
NRG-BN012, A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Protocol: 142302Principal Investigator:
- Nicholas DeNunzio MD, PhD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors.
Protocol: 112306Principal Investigator:
- Peter Cole M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System
- 1
- 2